



Review

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist

Michael Stephan Bader¹ and Sara Christina Meyer^{1,2,*}

¹ Division of Hematology, University Hospital Basel, CH-4031 Basel, Switzerland; michaelstephan.bader@usb.ch

² Department of Biomedicine, University Hospital Basel and University of Basel, CH-4031 Basel, Switzerland

* Correspondence: sara.meyer@unibas.ch

Abstract: The discovery of the activating V617F mutation in Janus kinase 2 (JAK2) has been decisive for the understanding of myeloproliferative neoplasms (MPN). Activated JAK2 signaling by *JAK2*, *CALR*, and *MPL* mutations has become a focus for the development of targeted therapies for patients with MPN. JAK2 inhibitors now represent a standard of clinical care for certain forms of MPN and offer important benefits for MPN patients. However, several key aspects remain unsolved regarding the targeted therapy of MPN with JAK2 inhibitors, such as reducing the MPN clone and how to avoid or overcome a loss of response. Here, we summarize the current knowledge on the structure and signaling of JAK2 as central elements of MPN pathogenesis and feature benefits and limitations of therapeutic JAK2 targeting in MPN.

Keywords: JAK2; myeloproliferative neoplasms; JAK2 inhibitors; resistance



Citation: Bader, M.S.; Meyer, S.C.

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist.

Pharmaceuticals **2022**, *15*, 160.

<https://doi.org/10.3390/ph15020160>

Academic Editors: Bobin

George Abraham and Anniina

T. Virtanen

Received: 29 December 2021

Accepted: 26 January 2022

Published: 28 January 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Janus kinases (JAKs) constitute a family of intracellular, non-receptor tyrosine kinases. They are associated with their corresponding cell surface receptors and transduce signals from cytokines, as well as some hormones, such as growth hormone and prolactin [1]. Mediation of extracellular signals via JAKs activates intracellular messenger pathways, impacting hematopoiesis, metabolism, and immune responses [2–4]. The discovery that most *BCR-ABL1*-negative myeloproliferative neoplasms (MPN) carry an activating *JAK2* mutation has moved this tyrosine kinase into the center of interest and has led to refined diagnostic criteria for these disease entities, development of new prognostic models, and the introduction of JAK inhibitors into clinical practice. Here, we review the role of JAK2 in myeloproliferative neoplasms (Supplementary Materials).

2. JAK2 Structure and Signaling

JAK2 and the additional Janus kinase family members JAK1, JAK3, and TYK2 share a similar structure with seven Janus homology (JH)-domains (JH1–JH7, Figure 1) [5,6]. The N-terminal FERM-domain (JH5–JH7), named after the proteins Band 4.1, ezrin, radixin, and moesin, and the Src homology 2 (SH2) domain mediate binding to the cytoplasmic portion of the associating cytokine receptors [7]. The C-terminal part of JAK2 contains the JH1 domain, which represents the catalytically active tyrosine kinase domain, and the so-called pseudokinase domain (JH2). The close proximity of the two kinase domains has led to the JAKs being named after the two-faced god Janus. Characterization of the structure, function, and regulation of JAK2 has been complicated by the challenging purification of the protein and its subunits. In case of the JH2-domain, only the exchange of three hydrophobic amino acids enabled the formation of protein crystals, which could subsequently be analyzed [8]. It has become clear that the pseudokinase domain has a regulatory impact on the JAK2 kinase domain via phosphorylation of S523 and Y570, mediating basal autoinhibition, which is reversed by stimulation of the associated cytokine receptor [9–11].




Figure 1. Schematic representation of the JAK2 domain structure. Seven Janus homology domains (JH1–JH7) constitute the N-terminal FERM and SH2 domain associating with the intracellular domains of cell surface receptors as well as the C-terminal pseudokinase and kinase domain of JAK2. The JAK2 V617F mutation locates to the pseudokinase domain, interfering with the basal inhibitory effect of the pseudokinase on the kinase domain, leading to constitutive JAK2 activation.

JAK2 activation occurs upon ligand binding to hematopoietic cytokine receptors such as the erythropoietin receptor (EPOR), thrombopoietin receptor (TPOR or MPL), or the granulocyte-macrophage colony-stimulating factor (GM-CSFR), as well as IL-3 and IL-5 receptors. JAK2 is also the mediator of signaling from growth hormone, leptin, and prolactin receptors [1] (Figure 2). Receptor dimerization enables transphosphorylation of the tandem tyrosines Y1007 and Y1008 in the activation loop of the JAK2 kinase domain, increasing catalytic activity [12].




Figure 2. The JAK-STAT signaling pathway in MPN.

Activated JAK2 mediates phosphorylation of its cognate receptors at the cytoplasmic tail and the generated phosphotyrosines serve as docking sites for SH2 domain-containing signaling proteins such as the signal transducer and activator of transcription (STATs). In MPN, STAT3 and STAT5 are phosphorylated, dimerize and translocate to the nucleus to regulate transcriptional programs, promoting cell proliferation, differentiation, and survival [3,13].

In addition, JAK2 also activates the mitogen-activated protein kinase (MAPK) pathway, which is implicated in many cancers (Figure 3, reviewed in Ref. [14]) and contains three evolutionarily conserved protein kinases including RAF, MEK1/2, and ERK1/2, as well as the PI3K/AKT/mTOR pathway (reviewed in Ref. [15]), which further enhance cell

proliferation and survival. Phosphorylation of PIM1 kinase and the Bcl-2 family member protein Bad inhibit apoptotic cell death and promote cell survival [2].




Figure 3. JAK2 signaling also activates MAPK and PI3K/Akt pathways, promoting cell proliferation and survival.

JAK2 signaling activity is negatively regulated by several factors, such as via negative feedback through suppressors of cytokine signaling (SOCS) proteins [16]. While the eight SOCS family members SOCS1-7 and the cytokine-inducible SH2-containing protein (CIS) are recruiting ubiquitin ligases (E3) to target JAK2 and other proteins for degradation, it has been shown that SOCS3 is able to directly inhibit JAK2 kinase activity via complex formation. In addition, phosphatases including SHP1 and SHP2 as well as other protein tyrosine phosphatases (PTPs) contribute to JAK2 inactivation via dephosphorylation of JAK2 and the associated receptors [17]. JAK2 signaling also induces LNK (also known as SH2B3) and other members of the SH2B family, which are established regulators of JAK2. LNK has been shown to bind to phosphorylated JAK2 via its SH2 domain in an erythropoietin- or thrombopoietin-dependent manner, thereby inhibiting erythropoiesis and thrombopoiesis [18]. Negative regulators of STATs, such as the protein inhibitors of STATs (PIAS), further contribute to limiting the activation of JAK2-STAT signaling via ubiquitinylation and subsequent proteasomal degradation [2].

3. Activated JAK2 Signaling in MPN

The JAK2 V617F gain-of-function mutation was identified in 2005 by several laboratories [19–22], and it has greatly advanced our insight into the pathogenesis of *BCR-ABL1*-negative MPN. It has also facilitated MPN diagnosis and has highlighted the key role of activated JAK2 signaling, thus providing a basis for rationally designed targeted therapies. The JAK2 V617F mutation is located in exon 14, i.e., in the pseudokinase domain of JAK2 on chromosome 9p24, and consists of a single nucleotide substitution (G1849T). Crystal structure analyses of the V617F mutant JAK2 pseudokinase domain have shown that steric

alterations interfering with the inhibitory effect of the pseudokinase on the kinase domain induce constitute activation of JAK2 [8,23]. Consequently, dysregulated STAT, as well as PI3K/AKT and MAPK pathway signaling, occurs downstream of the EPOR, MPL (or TPOR), and GM-CSFR, resulting in excessive production of mature myeloid blood cells.

The *JAK2* V617F mutation is found in the majority of MPN patients including all three subtypes, such as in 95% of patients with polycythemia vera (PV) and 50–60% of patients with essential thrombocythemia (ET) or myelofibrosis (MF) (Table 1) [24]. In addition, several missense mutations, small insertions, or deletions in exon 12 of *JAK2* were identified in 2007. *JAK2* exon 12 mutations are encountered in 2–3% of patients with PV and are absent in ET and PMF [25]. Patients may show isolated and more pronounced erythrocytosis independent of the specific exon 12 mutation. In contrast, patients with the *JAK2* V617F mutation often present with trilineage hyperplasia. Nevertheless, disease evolution and clinical outcome appear to be similar [26].

Table 1. Somatic mutations in myeloproliferative neoplasms (MPN). Mutation frequencies are indicated for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) [27,28]. *JAK2*, *CALR*, and *MPL* mutations are considered as driver mutations, while so-called high molecular risk (HMR) mutations confer adverse prognosis in myelofibrosis. BP-MPN blast phase MPN.

Gene/Mutation	Chromosome	PV	Mutational Frequency (%) ET	PMF
Driver mutations in MPN				
<i>JAK2</i> V617F (exon 14)	9p24	95	50–60	50–60
<i>JAK2</i> exon 12 mutations	9p24	2–3	-	-
<i>CALR</i>	19p13.2	<1	20–30	20–35
<i>MPL</i>	1p34	<1	1–5	5–9
High molecular risk (HMR) mutations in MF				
<i>ASXL1</i>	20q11.1			25–35
<i>EZH2</i>	7q36.1			1–10
				10–18
<i>SRSF2</i>	17q25.1			(enriched in BP-MPN)
				1–6
<i>IDH1/IDH2</i>	2q33.3/15q26.1			(enriched in BP-MPN)
Other mutations enriched in blast phase MPN				
<i>TP53</i>	17p13.1			1–5 (enriched in BP-MPN)

JAK2 signaling is also constitutively activated by acquired mutations in *MPL* encoding the thrombopoietin receptor, and calreticulin (*CALR*), a calcium-binding chaperone of the endoplasmic reticulum. Given their redundant effect, *MPL* and *CALR* mutations rarely co-occur with *JAK2* mutations. For *MPL*, missense mutations of codon 515 (W515K or W515L) in exon 10 are most common and result in constitutive receptor activation inducing overactive *JAK2* signaling [29]. *MPL* mutations are found in 3–5% of patients with ET and PMF, but not PV [30]. Mutations of *CALR* affect exon 9 and can mainly be assigned to two major categories [31,32]. In type 1, a deletion of 52 base pairs occurs, while type 2 is characterized by a five base pair insertion. Both types of *CALR* mutations induce a frameshift of one base pair, which results in the loss of the C-terminal KDEL sequence acting as an ER retention signal. Mutant *CALR* is secreted by the ER, associates with the thrombopoietin receptor, and can be detected at the cell surface, a finding that may prove useful for therapeutic approaches [33,34]. *CALR* mutations occur in 20–35% of patients with ET or PMF and are associated with more pronounced thrombocytosis, younger age, fewer thromboembolic events, and an overall more favorable prognosis compared to *JAK2* V617F mutant patients [35]. It is notable that even so-called “triple-negative” MPN patients who lack a driver mutation in *JAK2*, *CALR*, or *MPL* show activated *JAK2* signaling, highlighting the significance of the *JAK2* signaling network for MPN pathogenesis [36]. This finding also provides a rational basis for *JAK2* inhibitor treatment in triple-negative MPN patients.

Apart from its profound impact on signaling, mutant *JAK2* has also been shown to enter the nucleus and elicit epigenetic effects [37]. *JAK2* V617F phosphorylates histone

H3, which prevents binding of heterochromatin protein 1 α and results in altered gene expression [38]. Phosphorylation of protein arginine methyltransferase 5 (PRMT5) has analogous effects via decreased methylation of histone H2A and H4 [39]. PRMT5 inhibitors, either as a single agent or in combination with JAK1/2 inhibitors, reduce myeloproliferation in cell lines and mouse models [40].

In addition to constitutive activation of JAK2 signaling, persistent inflammation is increasingly recognized as an important driver of MPN development and progression [41]. JAK2 V617F-mutated hematopoietic stem cells show increased expression of inflammatory cytokines such as TNF α , IFN α , and TGF β . A relationship between chronic inflammation and clonal development was corroborated by the finding that TNF α promotes clonal expansion of JAK2 V617F-mutated cells, while the absence of TNF α in JAK2 V617F-transduced bone marrow cells was able to abolish the MPN phenotype in murine models [42]. Additionally, mutant JAK2 has been reported to induce elevated levels of reactive oxygen species (ROS) by downregulating catalase expression, which leads to elevated levels of reactive H₂O₂ [43]. The persistent inflammatory milieu in MPN has been shown to promote bone marrow fibrosis and constitutional symptoms, correlating with an unfavorable prognosis [44]. Thus, liquid biopsy-based biomarkers of inflammatory activity may prove useful for diagnostic and prognostic purposes in the future, such as in distinguishing MPN subtypes and assessing the risk of thrombotic events [45].

4. Clinical Presentation of MPN

Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell disorders and, based on activated JAK2 signaling, present with an excessive output of mature blood cells of one or more myeloid lineages [46]. When first described by William Dameshek in 1951, a hitherto unrevealed stimulus leading to proliferation of bone marrow cells was suggested to drive the MPN including PV, ET, and PMF [47]. While PV is characterized by erythrocytosis and potential thrombocytosis and neutrophilia, the hallmark of ET is isolated thrombocytosis. Primary myelofibrosis is characterized by enhanced, atypical megakaryopoiesis and cytoses in the pre-fibrotic phase and progressive bone marrow fibrosis and cytopenia in more advanced phases. Extramedullary hematopoiesis leading to hepatosplenomegaly is typical for all MPN and most pronounced in PMF, including the appearance of myeloid and erythroid precursors in the peripheral blood (leuko-erythroblastosis). Beyond the characteristic alterations of peripheral blood counts and bone marrow architecture, the JAK2, CALR, and MPL driver mutations have become biomarkers for the diagnosis of MPN and have been incorporated into the WHO classification of hematopoietic malignancies [46]. Specifically, the JAK2 V617F mutation is instrumental in differentiating polycythemia vera from secondary erythrocytosis. It is still incompletely understood how PV, ET, or MF phenotypes may arise upon presence of the same JAK2 V617F mutation. Several factors have been implicated, such as JAK2 V617F mutant allele burden, which is usually lower in ET and higher in PV and MF, as well as loss of heterozygosity by mitotic recombination at chromosome 9p, leading to homozygosity for JAK2 V617F. Furthermore, the acquisition order of the JAK2 V617F and additional non-driver mutations, such as in the TET2 gene, was shown to play a role in determining clinical MPN phenotypes [3,48,49].

The most frequent complications of MPN are thrombo-hemorrhagic events. MPN patients are at risk for both arterial and venous thromboses, affecting approximately 40% of patients with PV during the course of disease. Particularly, there is an increased susceptibility for thromboses in the hepato-portal and portal venous systems, and splanchnic thrombosis are typically seen [50]. It has become clear that the prothrombotic condition in MPN relates to multiple factors including erythrocytosis, leukocytosis, activation of platelets, but also alterations in plasmatic coagulation and NET formation. In addition, inflammatory stimuli are known to induce endothelial dysfunction with pro-adhesive surface properties, which facilitates leukocyte and platelet binding and activation [51]. JAK2 V617F expression in endothelial cells appears to promote such functional changes and an overall

inflammatory state of the vasculature [52]. Interestingly, *JAK2* V617F is associated with a higher thrombotic risk than *CALR* mutations, and influences of the mutant cell fraction have also been shown [53]. Bleeding events are an additional concern and can relate to acquired von Willebrand syndrome due to preferential consumption of large von Willebrand factor (VWF) multimers in settings of excessive thrombocytosis with counts > 1000–1500 G/L.

While both PV and ET can progress to secondary myelofibrosis referred to as Post-PV/Post-ET MF, the risk of transformation to secondary acute myeloid leukemia (AML) is highest in PMF (10-year risk 10–20%), followed by PV (2–4%) and ET (approximately 1%) [54]. Outcomes are generally poor, reflecting the prevalent unfavorable cytogenetic and molecular features, which render the leukemic clones less sensitive to standard chemotherapeutic agents. Leukemic transformation can arise from the *JAK2* V617F mutant hematopoietic stem/progenitor compartment, but may also present as *JAK2* V617F-negative AML. Leukemic blasts preferentially show mutations in one of the two isoforms of isocitrate dehydrogenase (*IDH1*, *IDH2*), the tumor suppressor gene *TP53*, or serine and arginine-rich splicing factor 2 (*SRSF2*) (Table 1) [55–57]. Risk of leukemic transformation is associated with the overall number of acquired mutations, and the vast majority of these are already detectable at MPN diagnosis [58].

5. Clinical Benefit of JAK Inhibitor Therapy in MPN

Constitutive activation of *JAK2* signaling in *JAK2*, *CALR*, and *MPL* mutant settings as well as in triple-negative MPN has provided a rational basis to develop *JAK2* inhibition as a therapeutic approach in MPN [34]. Current *JAK2* inhibitors that are approved (ruxolitinib, fedratinib) or in clinical development (mometotinib, pacritinib, etc.) engage the ATP-binding site of *JAK2* in the active conformation, thereby interfering with *JAK2* catalytic activity, and are referred to as type 1 inhibitors [59].

Ruxolitinib, which acts as a *JAK1/2* inhibitor, represents a clinical standard of care for patients with intermediate or high-risk MF with symptomatic splenomegaly or constitutional symptoms. As demonstrated by the COMFORT trials, ruxolitinib is able to improve splenomegaly and symptom burden along with reduced cytosines and proinflammatory cytokine levels. A survival benefit was observed after one year of treatment [60,61]. Based on the RESPONSE study, ruxolitinib has also been approved for patients with PV resistance or intolerant to hydroxyurea [62] and is effectively reducing hematocrit, splenomegaly, and symptom burden. Ruxolitinib therapy also resulted in a lower frequency of thromboembolic events relating to reduced hematocrit and inflammation [63]. In ET, ruxolitinib has not shown additional clinical value so far [64].

Fedratinib, a second *JAK*inib with *JAK2/FLT3* inhibitory activity, has recently been approved after clinical development was delayed by a clinical hold based on suspected cases of Wernicke's encephalopathy. Analogous to ruxolitinib, fedratinib is able to reduce symptom burden and splenomegaly in *JAK* inhibitor-naïve patients as well as in patients who lose response or are intolerant to ruxolitinib, thus providing a second line *JAK2* inhibitor treatment after ruxolitinib failure [65]. Monitoring of thiamine levels and/or supplementation is recommended and additional safety data from the phase 3b FREEDOM study are currently accumulating.

Several *JAK2* inhibitors are in clinical development, which could prove beneficial in patients with anemia and/or thrombocytopenia. Pacritinib is a *JAK2/FLT3* inhibitor with milder myelosuppressive properties and favorable results in patients with thrombocytopenia [66]. In addition, momelotinib represents a *JAK1/2* inhibitor with additional impact on the activin A type 1 receptor (*ACVR1*), which favorably affects iron homeostasis and translates into reduced transfusion requirements [67,68]. Pacritinib and momelotinib are currently being evaluated in clinical trials and will hopefully soon extend our therapeutic options for cytopenic MPN patients.

Beyond MPN, the *JAK1/2* inhibitor ruxolitinib has also shown activity in the therapy of glucocorticosteroid-refractory acute or chronic graft-versus-host disease [69,70]. Further-

more, immunosuppressive properties of JAK1/2 inhibitors are increasingly used to treat various autoimmune disorders, particularly rheumatoid arthritis.

6. Limitations of JAK Inhibitor Therapy in MPN

Current JAK2 inhibitor therapies in MPN show limited disease-modifying potential as an important limitation. Reductions in mutant allele burden are modest, and it has been demonstrated that clonal evolution is progressing during treatment with, e.g., ruxolitinib [71]. Continued therapy may lead to a certain decrease in clone size, but partial molecular remission, defined as a 50% reduction in JAK2 V617F allele burden in patients with at least 20% mutant allelic burden at baseline, is achieved in <10% of patients. Therefore, the development of more effective therapeutic approaches with disease-modifying potential is imperative.

Anemia, thrombocytopenia, and to a lesser extent immunosuppression represent frequent on-target toxicities of JAK inhibitor treatment and may require dose modifications [61,72]. While anemia is most pronounced at treatment initiation, it may stabilize over time.

JAK1 inhibitory activity of ruxolitinib has been related to reduced immune surveillance and the association with higher incidences of opportunistic infections and particularly reactivation of Herpes zoster, but also reactivation of tuberculosis, cryptococcal meningoencephalitis, *Pneumocystis jirovecii* pneumonia, hepatitis B, toxoplasmosis, or cytomegalovirus retinitis have been reported underscoring the importance of increased vigilance [73–77]. In addition, it has been speculated that MPN patients treated with ruxolitinib could be at higher risk for secondary cancers, and a trend for increased occurrence of non-melanoma skin cancer has been observed in long-term studies [78]. Furthermore, aggressive B-cell lymphomas have been reported, particularly in patients with MPN and preexisting B-cell clones, but the data are conflicting [79,80].

Loss of response to JAK inhibitor therapy can occur over time and is seen in approximately 50% of MF patients who initially responded to therapy after 5 years of treatment [81]. Second-site mutations inducing resistance by interference with drug binding have been described in MPN cell lines but have not been reported in MPN patients. Thus, resistance to JAK inhibitors appears to relate to adaptive processes, which is highlighted by the observation that patients can regain response upon re-exposure after a drug holiday [82]. While reactivation of JAK2 signaling via JAK family heterodimer formation has been described [83], additional mechanisms of acquired resistance to JAK2 inhibition have also been reported [84].

7. Potential Future Avenues for JAK2 Inhibitor Development and Alternative Therapeutic Approaches

While current JAK2 inhibitors in clinical development all act via ATP competitive binding to the active conformation of the JAK2 kinase domain (type 1 inhibition), perspectives for the future development of enhanced JAK2 inhibitors include several alternative approaches. Selective inhibition of JAK2 V617F represents an ultimate goal and would hopefully facilitate efforts to reduce MPN clone size. Type 2 JAK2 inhibition, which interferes with JAK2 in the inactive conformation, has shown promising effects on mutant allele burden in preclinical studies [85,86]. A different concept is the design of JAK2 pseudokinase inhibitors displacing ATP from the JAK2 JH2 domain. While minor effects on wild-type JAK2 have been detected, JH2 ATP binding appears to be critical for aberrant constitutive activity in JAK2 V617F [87]. Promising results are accumulating for combining JAK2 inhibition with the targeting of additional factors involved in MPN pathogenesis. Such dual approaches, which combine JAK2 inhibitors with Bcl-2/Bcl-xL inhibition, bromodomain inhibition, interferon-alpha, PI3K pathway, MAPK/ERK pathway inhibition, or others, are in clinical evaluation and highlight the significance as well as the promise of therapeutic developments in MPN [88–93].

8. JAK2 V617F in Clonal Hematopoiesis of Indeterminate Potential

Beyond MPN, the *JAK2* V617F mutation has recently been identified in clonal hematopoiesis of indeterminate potential (CHIP), a pre-malignant state that relates to the occurrence of a hematopoietic clone with somatic mutations known to be associated with myeloid neoplasms, but in a healthy individual with normal blood counts. The emergence of CHIP originates from a hematopoietic stem cell and is an age-dependent process, affecting approximately 10% of individuals over 70 years of age. Prevalence significantly depends on the applied method and its sensitivity to detect variant allele frequencies and may therefore be higher [94].

Along with mutations in *DNMT3A*, *TET2*, *ASXL1*, *SRSF2*, and *SF3B1*, *JAK2* V617F is among the most frequent mutations in CHIP [95]. Individuals carrying CHIP exhibit increased all-cause mortality, which is primarily attributable to a higher incidence of cardiovascular events rather than the elevated risk of developing hematopoietic neoplasms. The risk of developing coronary heart disease or ischemic stroke within 10 years was reported as roughly twofold in carriers of CHIP. In the presence of CHIP with an activating *JAK2* mutation, the risk of coronary heart disease was even further increased and reported to be approximately 12-fold [94]. The presence of CHIP is an independent cardiovascular risk factor and comparable to established risk factors, such as dyslipidemia, arterial hypertension, smoking, and diabetes mellitus. Likewise, venous thromboembolic events represent both initial manifestations of an underlying MPN but may also be associated with a *JAK2* V617F mutation without the clinical phenotype of a concomitant myeloid neoplasm. In a series of patients with normal blood counts, absence of panmyelosis, and apparently idiopathic hepatic venous thrombosis (Budd–Chiari syndrome), 50% harbored a *JAK2* V617F mutation. Moreover, 25% of all patients developed an MPN during follow-up, with ET diagnosed in approximately 75% [96]. While insight into the biology and clinical relevance of *JAK2* mutant CHIP is accumulating, questions regarding management and potential therapy are currently not clarified and warrant specific investigation in future studies.

9. Conclusions

Since the discovery of the *JAK2* V617F mutation, insight into the molecular pathogenesis of MPN has impressively increased and has provided a rational basis for the development of targeted therapy approaches. Novel *JAK2* inhibitors and combination therapies are expected to become part of clinical practice. *JAK2* remains central to disease understanding and a target in MPN.

Supplementary Materials: The following are available online at <https://www.mdpi.com/article/10.3390/ph15020160/s1>.

Author Contributions: M.S.B. and S.C.M. wrote and edited the paper. All authors have read and agreed to the published version of the manuscript.

Funding: This review article received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: Figures were created with BioRender ([Biorender.com](https://biorender.com), accessed on 29 December 2021).

Conflicts of Interest: SCM has consulted for and received honoraria from Celgene/BMS and Novartis. MSB has no conflicts of interest to declare.

References

1. Hammarén, H.M.; Virtanen, A.T.; Raivola, J.; Silvennoinen, O. The Regulation of JAKs in Cytokine Signaling and Its Breakdown in Disease. *Cytokine* **2019**, *118*, 48–63. [[CrossRef](#)] [[PubMed](#)]
2. Meyer, S.C.; Levine, R.L. Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors. *Clin. Cancer Res.* **2014**, *20*, 2051–2059. [[CrossRef](#)] [[PubMed](#)]

3. Skoda, R.C.; Duek, A.; Grisouard, J. Pathogenesis of Myeloproliferative Neoplasms. *Exp. Hematol.* **2015**, *43*, 599–608. [[CrossRef](#)] [[PubMed](#)]
4. O'Shea, J.J.; Plenge, R. JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease. *Immunity* **2012**, *36*, 542–550. [[CrossRef](#)] [[PubMed](#)]
5. McNally, R.; Toms, A.V.; Eck, M.J. Crystal Structure of the FERM-SH2 Module of Human Jak2. *PLoS ONE* **2016**, *11*, e0156218. [[CrossRef](#)] [[PubMed](#)]
6. Raivola, J.; Haikarainen, T.; Abraham, B.G.; Silvennoinen, O. Janus Kinases in Leukemia. *Cancers* **2021**, *13*, 800. [[CrossRef](#)]
7. Wallweber, H.J.A.; Tam, C.; Franke, Y.; Starovasnik, M.A.; Lupardus, P.J. Structural Basis of Recognition of Interferon- α Receptor by Tyrosine Kinase 2. *Nat. Struct. Mol. Biol.* **2014**, *21*, 443–448. [[CrossRef](#)]
8. Bandaranayake, R.M.; Ungureanu, D.; Shan, Y.; Shaw, D.E.; Silvennoinen, O.; Hubbard, S.R. Crystal Structures of the JAK2 Pseudokinase Domain and the Pathogenic Mutant V617F. *Nat. Struct. Mol. Biol.* **2012**, *19*, 754–759. [[CrossRef](#)]
9. Saharinen, P.; Takaluoma, K.; Silvennoinen, O. Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain. *Mol. Cell. Biol.* **2000**, *20*, 3387–3395. [[CrossRef](#)]
10. Argetsinger, L.S.; Kouadio, J.-L.K.; Steen, H.; Stensballe, A.; Jensen, O.N.; Carter-Su, C. Autophosphorylation of JAK2 on Tyrosines 221 and 570 Regulates Its Activity. *Mol. Cell. Biol.* **2004**, *24*, 4955–4967. [[CrossRef](#)]
11. Mazurkiewicz-Munoz, A.M.; Argetsinger, L.S.; Kouadio, J.-L.K.; Stensballe, A.; Jensen, O.N.; Cline, J.M.; Carter-Su, C. Phosphorylation of JAK2 at Serine 523: A Negative Regulator of JAK2 That Is Stimulated by GrowthHormone and Epidermal Growth Factor. *Mol. Cell. Biol.* **2006**, *26*, 4052–4062. [[CrossRef](#)] [[PubMed](#)]
12. Babon, J.J.; Lucet, I.S.; Murphy, J.M.; Nicola, N.A.; Varghese, L.N. The Molecular Regulation of Janus Kinase (JAK) Activation. *Biochem. J.* **2014**, *462*, 1–13. [[CrossRef](#)] [[PubMed](#)]
13. Villarino, A.V.; Kanno, Y.; O'Shea, J.J. Mechanisms and Consequences of Jak-STAT Signaling in the Immune System. *Nat. Immunol.* **2017**, *18*, 374–384. [[CrossRef](#)] [[PubMed](#)]
14. Guo, Y.; Pan, W.; Liu, S.; Shen, Z.; Xu, Y.; Hu, L. ERK/MAPK Signalling Pathway and Tumorigenesis (Review). *Exp. Ther. Med.* **2020**, *19*, 1997–2007. [[CrossRef](#)] [[PubMed](#)]
15. Nepstad, I.; Hatfield, K.J.; Grønningsæter, I.S.; Reikvam, H. The PI3K-AKT-MTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. *Int. J. Mol. Sci.* **2020**, *21*, 2907. [[CrossRef](#)] [[PubMed](#)]
16. Varghese, L.N.; Ungureanu, D.; Liao, N.P.D.; Young, S.N.; Laktyushin, A.; Hammaren, H.; Lucet, I.S.; Nicola, N.A.; Silvennoinen, O.; Babon, J.J.; et al. Mechanistic Insights into Activation and SOCS3-Mediated Inhibition of Myeloproliferative Neoplasm-Associated JAK2 Mutants from Biochemical and Structural Analyses. *Biochem. J.* **2014**, *458*, 395–405. [[CrossRef](#)]
17. Xu, D.; Qu, C.K. Protein Tyrosine Phosphatases in the JAK/STAT Pathway. *Front. Biosci.* **2008**, *13*, 4925–4932. [[CrossRef](#)]
18. Maslah, N.; Cassinat, B.; Verger, E.; Kiladjian, J.J.; Velazquez, L. The Role of LNK/SH2B3 Genetic Alterations in Myeloproliferative Neoplasms and Other Hematological Disorders. *Leukemia* **2017**, *31*, 1661–1670. [[CrossRef](#)]
19. Levine, R.L.; Wadleigh, M.; Cools, J.; Ebert, B.L.; Wernig, G.; Huntly, B.J.P.; Boggon, T.J.; Wlodarska, I.; Clark, J.J.; Moore, S.; et al. Activating Mutation in the Tyrosine Kinase JAK2 in Polycythemia Vera, Essential Thrombocythemia, and Myeloid Metaplasia with Myelofibrosis. *Cancer Cell* **2005**, *7*, 387–397. [[CrossRef](#)]
20. Kralovics, R.; Passamonti, F.; Buser, A.S.; Teo, S.; Tiedt, R.; Passweg, J.R.; Tichelli, A.; Cazzola, M.; Skoda, R.C. A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders. *N. Engl. J. Med.* **2005**, *352*, 1779–1790. [[CrossRef](#)]
21. Baxter, E.J.; Scott, L.M.; Campbell, P.J.; East, C.; Fourouclas, N.; Swanton, S.; Vassiliou, G.S.; Bench, A.J.; Boyd, E.M.; Curtin, N.; et al. Acquired Mutation of the Tyrosine Kinase JAK2 in Human Myeloproliferative Disorders. *Lancet* **2005**, *365*, 1054–1061. [[CrossRef](#)]
22. Ugo, V.; James, C.; Vainchenker, W. A Unique Clonal JAK2 Mutation Leading to Constitutive Signalling Causes Polycythaemia Vera. *Medicine/Sciences* **2005**, *21*, 669–670. [[CrossRef](#)]
23. Shan, Y.; Gnanasambandan, K.; Ungureanu, D.; Kim, E.T.; Hammarén, H.; Yamashita, K.; Silvennoinen, O.; Shaw, D.E.; Hubbard, S.R. Molecular Basis for Pseudokinase-Dependent Autoinhibition of JAK2 Tyrosine Kinase. *Nat. Struct. Mol. Biol.* **2014**, *21*, 579–584. [[CrossRef](#)]
24. Szybinski, J.; Meyer, S.C. Genetics of Myeloproliferative Neoplasms. *Hematol. Oncol. Clin. N. Am.* **2021**, *35*, 217–236. [[CrossRef](#)]
25. Scott, L.M.; Tong, W.; Levine, R.L.; Scott, M.A.; Beer, P.A.; Stratton, M.R.; Futreal, P.A.; Erber, W.N.; McMullin, M.F.; Harrison, C.N.; et al. JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis. *N. Engl. J. Med.* **2007**, *356*, 459–468. [[CrossRef](#)]
26. Passamonti, F.; Elena, C.; Schnittger, S.; Skoda, R.C.; Green, A.R.; Girodon, F.; Kiladjian, J.J.; McMullin, M.F.; Ruggeri, M.; Besses, C.; et al. Molecular and Clinical Features of the Myeloproliferative Neoplasm Associated with JAK2 Exon 12 Mutations. *Blood* **2011**, *117*, 2813–2816. [[CrossRef](#)]
27. Tefferi, A. Primary Myelofibrosis: 2021 Update on Diagnosis, Risk-Stratification and Management. *Am. J. Hematol.* **2021**, *96*, 145–162. [[CrossRef](#)]
28. Vainchenker, W.; Kralovics, R. Genetic Basis and Molecular Pathophysiology of Classical Myeloproliferative Neoplasms. *Blood* **2017**, *129*, 667–679. [[CrossRef](#)]
29. Pikman, Y.; Lee, B.H.; Mercher, T.; McDowell, E.; Ebert, B.L.; Gozo, M.; Cuker, A.; Wernig, G.; Moore, S.; Galinsky, I.; et al. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. *PLoS Med.* **2006**, *3*, 1140–1151. [[CrossRef](#)]

30. Pardanani, A.D.; Levine, R.L.; Lasho, T.; Pikman, Y.; Mesa, R.A.; Wadleigh, M.; Steensma, D.P.; Elliott, M.A.; Wolanskyj, A.P.; Hogan, W.J.; et al. MPL515 Mutations in Myeloproliferative and Other Myeloid Disorders: A Study of 1182 Patients. *Blood* **2006**, *108*, 3472–3476. [[CrossRef](#)]
31. Klampfl, T.; Gisslinger, H.; Harutyunyan, A.S.; Nivarthi, H.; Rumi, E.; Milosevic, J.D.; Them, N.C.C.; Berg, T.; Gisslinger, B.; Pietra, D.; et al. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. *N. Engl. J. Med.* **2013**, *369*, 2379–2390. [[CrossRef](#)]
32. Nangalia, J.; Massie, C.E.; Baxter, E.J.; Nice, F.L.; Gundem, G.; Wedge, D.C.; Avezov, E.; Li, J.; Kollmann, K.; Kent, D.G.; et al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. *N. Engl. J. Med.* **2013**, *369*, 2391–2405. [[CrossRef](#)]
33. Elf, S.; Abdelfattah, N.S.; Chen, E.; Perales-Patón, J.; Rosen, E.A.; Ko, A.; Peisker, F.; Florescu, N.; Giannini, S.; Wolach, O.; et al. Mutant Calreticulin Requires Both Its Mutant C-Terminus and the Thrombopoietin Receptor for Oncogenic Transformation. *Cancer Discov.* **2016**, *6*, 368–381. [[CrossRef](#)]
34. Chachoua, I.; Pecquet, C.; El-Khoury, M.; Nivarthi, H.; Albu, R.I.; Marty, C.; Gryshkova, V.; Defour, J.P.; Vertenoeil, G.; Ngo, A.; et al. Thrombopoietin Receptor Activation by Myeloproliferative Neoplasm Associated Calreticulin Mutants. *Blood* **2016**, *127*, 1325–1335. [[CrossRef](#)]
35. Rumi, E.; Pietra, D.; Ferretti, V.; Klampfl, T.; Harutyunyan, A.S.; Milosevic, J.D.; Them, N.C.C.; Berg, T.; Elena, C.; Casetti, I.C.; et al. JAK2 or CALR Mutation Status Defines Subtypes of Essential Thrombocythemia with Substantially Different Clinical Course and Outcomes. *Blood* **2014**, *123*, 1544–1551. [[CrossRef](#)]
36. Rampal, R.; Al-Shahrour, F.; Abdel-Wahab, O.; Patel, J.P.; Brunel, J.P.; Mermel, C.H.; Bass, A.J.; Pretz, J.; Ahn, J.; Hricik, T.; et al. Integrated Genomic Analysis Illustrates the Central Role of JAK-STAT Pathway Activation in Myeloproliferative Neoplasm Pathogenesis. *Blood* **2014**, *123*, e123–e133. [[CrossRef](#)]
37. Rinaldi, C.R.; Rinaldi, P.; Alagia, A.; Gemei, M.; Esposito, N.; Formiggini, F.; Martinelli, V.; Senyuk, V.; Nucifora, G.; Pane, F. Preferential Nuclear Accumulation of JAK2V617F in CD34+ but Not in Granulocytic, Megakaryocytic, or Erythroid Cells of Patients with Philadelphia-Negative Myeloproliferative Neoplasia. *Blood* **2010**, *116*, 6023–6026. [[CrossRef](#)]
38. Dawson, M.A.; Bannister, A.J.; Göttgens, B.; Foster, S.D.; Bartke, T.; Green, A.R.; Kouzarides, T. JAK2 Phosphorylates Histone H3Y41 and Excludes HP1 α from Chromatin. *Nature* **2009**, *461*, 819–822. [[CrossRef](#)]
39. Liu, F.; Zhao, X.; Perna, F.; Wang, L.; Koppikar, P.; Abdel-Wahab, O.; Harr, M.W.; Levine, R.L.; Xu, H.; Tefferi, A.; et al. JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation. *Cancer Cell* **2011**, *19*, 283–294. [[CrossRef](#)]
40. Pastore, F.; Bhagwat, N.; Pastore, A.; Radziszewska, A.; Karzai, A.; Krishnan, A.; Li, B.; Bowman, R.L.; Xiao, W.; Viny, A.D.; et al. PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN. *Cancer Discov.* **2020**, *10*, 1742–1757. [[CrossRef](#)]
41. Di Battista, V.; Bochicchio, M.T.; Giordano, G.; Napolitano, M.; Lucchesi, A. Review Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review. *Int. J. Mol. Sci.* **2021**, *22*, 561. [[CrossRef](#)] [[PubMed](#)]
42. Fleischman, A.G.; Aichberger, K.J.; Luty, S.B.; Bumm, T.G.; Petersen, C.L.; Doratotaj, S.; Vasudevan, K.B.; LaTocha, D.H.; Yang, F.; Press, R.D.; et al. TNF α Facilitates Clonal Expansion of JAK2V617F Positive Cells in Myeloproliferative Neoplasms. *Blood* **2011**, *118*, 6392–6398. [[CrossRef](#)] [[PubMed](#)]
43. Marty, C.; Lacout, C.; Droin, N.; Le Couédic, J.P.; Ribrag, V.; Solary, E.; Vainchenker, W.; Villeval, J.L.; Plo, I. A Role for Reactive Oxygen Species in JAK2 V617F Myeloproliferative Neoplasm Progression. *Leukemia* **2013**, *27*, 2187–2195. [[CrossRef](#)] [[PubMed](#)]
44. Hasselbalch, H.C. The Role of Cytokines in the Initiation and Progression of Myelofibrosis. *Cytokine Growth Factor Rev.* **2013**, *24*, 133–145. [[CrossRef](#)]
45. Găman, M.A.; Cozma, M.A.; Dobrică, E.C.; Crețoiu, S.M.; Găman, A.M.; Diaconu, C.C. Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review. *Life* **2021**, *11*, 677. [[CrossRef](#)]
46. Arber, D.A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M.J.; Le Beau, M.M.; Bloomfield, C.D.; Cazzola, M.; Vardiman, J.W. The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia. *Blood* **2016**, *127*, 2391–2405. [[CrossRef](#)]
47. DAMESHEK, W. Some Speculations on the Myeloproliferative Syndromes. *Blood* **1951**, *6*, 372–375. [[CrossRef](#)]
48. Godfrey, A.L.; Chen, E.; Pagano, F.; Ortmann, C.A.; Silber, Y.; Bellosillo, B.; Guglielmelli, P.; Harrison, C.N.; Reilly, J.T.; Stegelmann, F.; et al. JAK2V617F Homozygosity Arises Commonly and Recurrently in PV and ET, but PV Is Characterized by Expansion of a Dominant Homozygous Subclone. *Blood* **2012**, *120*, 2704–2707. [[CrossRef](#)]
49. Ortmann, C.A.; Kent, D.G.; Nangalia, J.; Silber, Y.; Wedge, D.C.; Grinfeld, J.; Baxter, E.J.; Massie, C.E.; Papaemmanuil, E.; Menon, S.; et al. Effect of Mutation Order on Myeloproliferative Neoplasms. *N. Engl. J. Med.* **2015**, *372*, 601–612. [[CrossRef](#)] [[PubMed](#)]
50. Falanga, A.; Marchetti, M. Thrombosis in Myeloproliferative Neoplasms. *Semin. Thromb. Hemost.* **2014**, *40*, 348–358. [[CrossRef](#)]
51. Shao, Y.; Cheng, Z.; Li, X.; Chernaya, V.; Wang, H.; Yang, X.F. Immunosuppressive/Anti-Inflammatory Cytokines Directly and Indirectly Inhibit Endothelial Dysfunction-A Novel Mechanism for Maintaining Vascular Function. *J. Hematol. Oncol.* **2014**, *7*, 80. [[CrossRef](#)] [[PubMed](#)]

52. Guy, A.; Gourdou-Latyszenok, V.; Le Lay, N.; Peghaire, C.; Kilani, B.; Dias, J.V.; Duplaa, C.; Renault, M.A.; Denis, C.; Villeval, J.L.; et al. Vascular Endothelial Cell Expression of JAK2 V617F Is Sufficient to Promote a Pro-Thrombotic State Due to Increased P-Selectin Expression. *Haematologica* **2019**, *104*, 70–81. [[CrossRef](#)] [[PubMed](#)]
53. Guglielmelli, P.; Barosi, G.; Specchia, G.; Rambaldi, A.; Lo Coco, F.; Antonioli, E.; Pieri, L.; Pancrazzi, A.; Ponziani, V.; Delaini, F.; et al. Identification of Patients with Poorer Survival in Primary Myelofibrosis Based on the Burden of JAK2V617F Mutated Allele. *Blood* **2009**, *114*, 1477–1483. [[CrossRef](#)] [[PubMed](#)]
54. Tefferi, A.; Guglielmelli, P.; Larson, D.R.; Finke, C.; Wassie, E.A.; Pieri, L.; Gangat, N.; Fjerza, R.; Belachew, A.A.; Lasho, T.L.; et al. Long-Term Survival and Blast Transformation in Molecularly Annotated Essential Thrombocythemia, Polycythemia Vera, and Myelofibrosis. *Blood* **2014**, *124*, 2507–2513. [[CrossRef](#)] [[PubMed](#)]
55. Tefferi, A.; Lasho, T.L.; Abdel-Wahab, O.; Guglielmelli, P.; Patel, J.; Caramazza, D.; Pieri, L.; Finke, C.M.; Kilpivaara, O.; Wadleigh, M.; et al. IDH1 and IDH2 Mutation Studies in 1473 Patients with Chronic-, Fibrotic- or Blast-Phase Essential Thrombocythemia, Polycythemia Vera or Myelofibrosis. *Leukemia* **2010**, *24*, 1302–1309. [[CrossRef](#)] [[PubMed](#)]
56. Zhang, S.J.; Rampal, R.; Manshouri, T.; Patel, J.; Mensah, N.; Kayserian, A.; Hricik, T.; Heguy, A.; Hedvat, C.; Gönen, M.; et al. Genetic Analysis of Patients with Leukemic Transformation of Myeloproliferative Neoplasms Shows Recurrent SRSF2 Mutations That Are Associated with Adverse Outcome. *Blood* **2012**, *119*, 4480–4485. [[CrossRef](#)] [[PubMed](#)]
57. Rampal, R.; Ahn, J.; Abdel-Wahaba, O.; Nahas, M.; Wang, K.; Lipson, D.; Otto, G.A.; Yelensky, R.; Hricik, T.; McKenney, A.S.; et al. Genomic and Functional Analysis of Leukemic Transformation of Myeloproliferative Neoplasms. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, E5401–E5410. [[CrossRef](#)]
58. Lundberg, P.; Karow, A.; Nienhold, R.; Looser, R.; Hao-Shen, H.; Nissen, I.; Girsberger, S.; Lehmann, T.; Passweg, J.; Stern, M.; et al. Clonal Evolution and Clinical Correlates of Somatic Mutations in Myeloproliferative Neoplasms. *Blood* **2014**, *123*, 2220–2228. [[CrossRef](#)]
59. Brkic, S.; Meyer, S.C. Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms. *Hemasphere* **2021**, *5*, e516. [[CrossRef](#)]
60. Verstovsek, S.; Mesa, R.A.; Gotlib, J.; Levy, R.S.; Gupta, V.; DiPersio, J.F.; Catalano, J.V.; Deininger, M.; Miller, C.; Silver, R.T.; et al. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. *N. Engl. J. Med.* **2012**, *366*, 799–807. [[CrossRef](#)]
61. Harrison, C.N.; Vannucchi, A.M.; Kiladjian, J.J.; Al-Ali, H.K.; Gisslinger, H.; Knoop, L.; Cervantes, F.; Jones, M.M.; Sun, K.; McQuitty, M.; et al. Long-Term Findings from COMFORT-II, a Phase 3 Study of Ruxolitinib vs Best Available Therapy for Myelofibrosis. *Leukemia* **2016**, *30*, 1701–1707. [[CrossRef](#)] [[PubMed](#)]
62. Vannucchi, A.M.; Kiladjian, J.J.; Griesshammer, M.; Masszi, T.; Durrant, S.; Passamonti, F.; Harrison, C.N.; Pane, F.; Zachee, P.; Mesa, R.; et al. Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. *N. Engl. J. Med.* **2015**, *372*, 426–435. [[CrossRef](#)] [[PubMed](#)]
63. Marchioli, R.; Finazzi, G.; Specchia, G.; Cacciola, R.; Cavazzina, R.; Cilloni, D.; De Stefano, V.; Elli, E.; Iurlo, A.; Latagliata, R.; et al. CYTO-PV Collaborative Group. Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. *N. Engl. J. Med.* **2013**, *368*, 22–33. [[CrossRef](#)] [[PubMed](#)]
64. Harrison, C.N.; Mead, A.J.; Panchal, A.; Fox, S.; Yap, C.; Gbandi, E.; Houlton, A.; Alimam, S.; Ewing, J.; Wood, M.; et al. Ruxolitinib vs. Best Available Therapy for Intolerant or Resistant to Hydroxycarbamide. *Blood* **2017**, *130*, 1889–1897. [[CrossRef](#)]
65. Pardanani, A.; Harrison, C.; Cortes, J.E.; Cervantes, F.; Mesa, R.A.; Milligan, D.; Masszi, T.; Mishchenko, E.; Jourdan, E.; Vannucchi, A.M.; et al. Safety and Efficacy of Fedratinib in Patients with Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. *JAMA Oncol.* **2015**, *1*, 643–651. [[CrossRef](#)]
66. Mascarenhas, J.; Hoffman, R.; Talpaz, M.; Gerds, A.T.; Stein, B.; Gupta, V.; Szoke, A.; Drummond, M.; Pristupa, A.; Granston, T.; et al. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients with Myelofibrosis: A Randomized Clinical Trial. *JAMA Oncol.* **2018**, *4*, 652–659. [[CrossRef](#)]
67. Oh, S.T.; Talpaz, M.; Gerds, A.T.; Gupta, V.; Verstovsek, S.; Mesa, R.; Miller, C.B.; Rivera, C.E.; Fleischman, A.G.; Goel, S.; et al. ACVR1/JAK1/JAK2 Inhibitor Momelotinib Reverses Transfusion Dependency and Suppresses Hepcidin in Myelofibrosis Phase 2 Trial. *Blood Adv.* **2020**, *4*, 4282–4291. [[CrossRef](#)]
68. Gupta, V.; Mesa, R.A.; Deininger, M.W.N.; Rivera, C.E.; Sirhan, S.; Brachmann, C.B.; Collins, H.; Kawashima, J.; Xin, Y.; Verstovsek, S. A Phase 1/2, Open-Label Study Evaluating Twice-Daily Administration of Momelotinib in Myelofibrosis. *Haematologica* **2017**, *102*, 94–102. [[CrossRef](#)]
69. Zeiser, R.; von Bubnoff, N.; Butler, J.; Mohty, M.; Niederwieser, D.; Or, R.; Szer, J.; Wagner, E.M.; Zuckerman, T.; Mahuzier, B.; et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. *N. Engl. J. Med.* **2020**, *382*, 1800–1810. [[CrossRef](#)]
70. Zeiser, R.; Polverelli, N.; Ram, R.; Hashmi, S.K.; Chakraverty, R.; Middeke, J.M.; Musso, M.; Giebel, S.; Uzay, A.; Langmuir, P.; et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. *N. Engl. J. Med.* **2021**, *385*, 228–238. [[CrossRef](#)]
71. Newberry, K.J.; Patel, K.; Masarova, L.; Luthra, R.; Manshouri, T.; Jabbour, E.; Bose, P.; Daver, N.; Cortes, J.; Kantarjian, H.; et al. Clonal Evolution and Outcomes in Myelofibrosis after Ruxolitinib Discontinuation. *Blood* **2017**, *130*, 1125–1131. [[CrossRef](#)] [[PubMed](#)]
72. Kiladjian, J.J.; Zachee, P.; Hino, M.; Pane, F.; Masszi, T.; Harrison, C.N.; Mesa, R.; Miller, C.B.; Passamonti, F.; Durrant, S.; et al. Long-Term Efficacy and Safety of Ruxolitinib versus Best Available Therapy in Polycythemia Vera (RESPONSE): 5-Year Follow up of a Phase 3 Study. *Lancet Haematol.* **2020**, *7*, e226–e237. [[CrossRef](#)]

73. Luo, Q.; Xiao, Z.; Peng, L. Effects of Ruxolitinib on Infection in Patients with Myeloproliferative Neoplasm: A Meta-Analysis. *Hematology* **2021**, *26*, 663–669. [[CrossRef](#)] [[PubMed](#)]
74. Sadjadian, P.; Wille, K.; Griesshammer, M.; Sadjadian, P.; Wille, K.; Griesshammer, M. Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations. *Cancers* **2020**, *12*, 3132. [[CrossRef](#)] [[PubMed](#)]
75. Khalid, F.; Damlaj, M.; AlZahrani, M.; Abuelgasim, K.A.; Gmati, G.E. Reactivation of Tuberculosis Following Ruxolitinib Therapy for Primary Myelofibrosis: Case Series and Literature Review. *Hematol. Oncol. Stem Cell Ther.* **2021**, *14*, 252–256. [[CrossRef](#)]
76. Duan, M.-H.; Cao, X.-X.; Chang, L.; Zhou, D.-B. Risk of Hepatitis B Virus Reactivation Following Ruxolitinib Treatment in Patients with Myeloproliferative Neoplasms. *Hematology* **2021**, *26*, 460–464. [[CrossRef](#)]
77. Devos, T.; Selleslag, D.; Granacher, N.; Havelange, V.; Benghiat, F.S. Updated Recommendations on the Use of Ruxolitinib for the Treatment of Myelofibrosis. *Hematology* **2022**, *27*, 23–31. [[CrossRef](#)]
78. Barraco, F.; Greil, R.; Herbrecht, R.; Schmidt, B.; Reiter, A.; Willenbacher, W.; Raymakers, R.; Liersch, R.; Wroclawska, M.; Pack, R.; et al. Real-World Non-Interventional Long-Term Post-Authorisation Safety Study of Ruxolitinib in Myelofibrosis. *Br. J. Haematol.* **2020**, *191*, 764–774. [[CrossRef](#)]
79. Porpacz, E.; Tripolt, S.; Hoelbl-Kovacic, A.; Gisslinger, B.; Bago-Horvath, Z.; Casanova-Hevia, E.; Clappier, E.; Decker, T.; Fajmann, S.; Fux, D.A.; et al. Aggressive B-Cell Lymphomas in Patients with Myelofibrosis Receiving JAK1/2 Inhibitor Therapy. *Blood* **2018**, *132*, 694–706. [[CrossRef](#)]
80. Sekhri, R.; Sadjadian, P.; Becker, T.; Kolatzki, V.; Huenerbein, K.; Meixner, R.; Marchi, H.; Wallmann, R.; Fuchs, C.; Griesshammer, M.; et al. Ruxolitinib-Treated Polycythemia Vera Patients and Their Risk of Secondary Malignancies. *Ann. Hematol.* **2021**, *100*, 2707–2716. [[CrossRef](#)]
81. Verstovsek, S.; Mesa, R.A.; Gotlib, J.; Gupta, V.; DiPersio, J.F.; Catalano, J.V.; Deininger, M.W.N.; Miller, C.B.; Silver, R.T.; Talpaz, M.; et al. Long-Term Treatment with Ruxolitinib for Patients with Myelofibrosis: 5-Year Update from the Randomized, Double-Blind, Placebo-Controlled, Phase 3 COMFORT-I Trial. *J. Hematol. Oncol.* **2017**, *10*, 55. [[CrossRef](#)] [[PubMed](#)]
82. Gisslinger, H.; Schalling, M.; Gisslinger, B.; Skrabs, C.; Müllauer, L.; Kralovics, R. Restoration of Response to Ruxolitinib upon Brief Withdrawal in Two Patients with Myelofibrosis. *Am. J. Hematol.* **2014**, *89*, 344–346. [[CrossRef](#)] [[PubMed](#)]
83. Koppikar, P.; Bhagwat, N.; Kilpivaara, O.; Manshour, T.; Adli, M.; Hricik, T.; Liu, F.; Saunders, L.M.; Mullally, A.; Abdel-Wahab, O.; et al. Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy. *Nature* **2012**, *489*, 155–159. [[CrossRef](#)] [[PubMed](#)]
84. Meyer, S.C. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms. *Hematol. Oncol. Clin. N. Am.* **2017**, *31*, 627–642. [[CrossRef](#)]
85. Meyer, S.C.; Keller, M.D.; Chiu, S.; Koppikar, P.; Guryanova, O.A.; Rapaport, F.; Xu, K.; Manova, K.; Pankov, D.; O'Reilly, R.J.; et al. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. *Cancer Cell* **2015**, *28*, 15–28. [[CrossRef](#)]
86. Wu, S.; Li, L.S.; Kopp, N.; Montero, J.; Chapuy, B.; Yoda, A.; Christie, A.L.; Liu, H.; Christodoulou, A.; van Bodegom, D.; et al. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. *Cancer Cell* **2015**, *28*, 29–41. [[CrossRef](#)]
87. Hammarén, H.M.; Ungureanu, D.; Grisouard, J.; Skoda, R.C.; Hubbard, S.R.; Silvennoinen, O. ATP Binding to the Pseudokinase Domain of JAK2 Is Critical for Pathogenic Activation. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 4642–4647. [[CrossRef](#)]
88. Harrison, C.; Garcia, J.S.; Mesa, R.; Somerville, T.; Ritchie, E.K.; Komrokji, R.S.; Pemmaraju, N.; Jamieson, C.; Papadantonakis, N.; Foran, J.M.; et al. MPN-038: Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis: A Phase 2 Study. *Clin. Lymphoma Myeloma Leuk.* **2020**, *20*, S325. [[CrossRef](#)]
89. Waibel, M.; Solomon, V.S.; Knight, D.A.; Ralli, R.A.; Kim, S.K.; Banks, K.M.; Vidacs, E.; Virely, C.; Sia, K.C.S.; Bracken, L.S.; et al. Combined Targeting of JAK2 and Bcl-2/Bcl-XL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors. *Cell Rep.* **2013**, *5*, 1047–1059. [[CrossRef](#)]
90. Yacoub, A.; Borate, U.; Rampal, R.; Ali, H.; Wang, E.; Gerds, A.; Hobbs, G.; Kremianskaya, M.; Winton, E.; O'Connell, C.; et al. MPN-127: Add-On Parsaclisib (a PI3K5 Inhibitor) in Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis from a Phase 2 Study. *Clin. Lymphoma Myeloma Leuk.* **2021**, *21*, S354–S355. [[CrossRef](#)]
91. Stivala, S.; Codilupi, T.; Brkic, S.; Baerenwaldt, A.; Ghosh, N.; Hao-Shen, H.; Dirnhofer, S.; Dettmer, M.S.; Simillion, C.; Kaufmann, B.A.; et al. Targeting Compensatory MEK/ERK Activation Increases JAK Inhibitor Efficacy in Myeloproliferative Neoplasms. *J. Clin. Invest.* **2019**, *129*, 1596–1611. [[CrossRef](#)] [[PubMed](#)]
92. Brkic, S.; Stivala, S.; Santopolo, A.; Szybinski, J.; Jungius, S.; Passweg, J.R.; Tsakiris, D.; Dirnhofer, S.; Hutter, G.; Leonards, K.; et al. Dual Targeting of JAK2 and ERK Interferes with the Myeloproliferative Neoplasm Clone and Enhances Therapeutic Efficacy. *Leukemia* **2021**, *35*, 2875–2884. [[CrossRef](#)] [[PubMed](#)]
93. Jayavelu, A.K.; Schnöder, T.M.; Perner, F.; Herzog, C.; Meiler, A.; Krishnamoorthy, G.; Huber, N.; Mohr, J.; Edelmann-Stephan, B.; Austin, R.; et al. Splicing Factor YBX1 Mediates Persistence of JAK2-Mutated Neoplasms. *Nature* **2020**, *588*, 157–163. [[CrossRef](#)] [[PubMed](#)]
94. Jaiswal, S.; Natarajan, P.; Silver, A.J.; Gibson, C.J.; Bick, A.G.; Shvartz, E.; McConkey, M.; Gupta, N.; Gabriel, S.; Ardissino, D.; et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. *N. Engl. J. Med.* **2017**, *377*, 111–121. [[CrossRef](#)] [[PubMed](#)]

-
95. Xie, M.; Lu, C.; Wang, J.; McLellan, M.D.; Johnson, K.J.; Wendl, M.C.; McMichael, J.F.; Schmidt, H.K.; Yellapantula, V.; Miller, C.A.; et al. Age-Related Mutations Associated with Clonal Hematopoietic Expansion and Malignancies. *Nat. Med.* **2014**, *20*, 1472–1478. [[CrossRef](#)]
 96. Patel, R.K.; Lea, N.C.; Heneghan, M.A.; Westwood, N.B.; Milojkovic, D.; Thanigaikumar, M.; Yallop, D.; Arya, R.; Pagliuca, A.; Gäken, J.; et al. Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome. *Gastroenterology* **2006**, *130*, 2031–2038. [[CrossRef](#)]